Viking Therapeutics shares jump 38% as VK2735 data shows weight loss maintenance on reduced dosing

Key points

• Viking Therapeutics (VKTX) shares spiked approximately 38% premarket on September 22, 2026, reaching a high of $42, approaching its 52-week high of $43.15.
• The stock move followed the release of top-line results from a 180-patient maintenance study for VK2735, a dual GLP-1/GIP receptor agonist.
• In the study, patients who lost 16% to 19% of body weight on weekly injections maintained up to 97% of that loss when switched to every-other-week dosing for 12 weeks.
• Monthly dosing preserved up to 90% of weight loss, compared to 61% for the placebo group, with gastrointestinal side effects comparable to placebo.
• Viking is currently conducting Phase 3 trials for the injectable form with approximately 5,500 patients and plans to test oral maintenance dosing later in 2026.

Background

The obesity drug market has been dominated by Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy, with global sales projected to reach $114 billion by 2030. Recent industry discussions have focused on strategies to sustain weight loss after initial treatment, including nutritional adjustments and muscle-preserving therapies. Viking’s data addresses the critical challenge of long-term adherence and maintenance, a key differentiator in a crowded therapeutic landscape.

How outlets are covering it

Yahoo Finance emphasized the stock’s technical breakout and retail investor enthusiasm, noting a shift to 'extremely bullish' sentiment on Stocktwits. Investing.com highlighted the clinical significance of the results, noting that the data validates the hypothesis that reduced dosing frequency can maintain efficacy, a key competitive battleground. Moomoo framed the news as a potential challenge to the market dominance of Eli Lilly and Novo Nordisk. All sources agreed on the magnitude of the stock surge and the efficacy data, but differed in emphasis: Yahoo focused on market reaction, Investing.com on clinical validation, and Moomoo on competitive implications.

Why it matters

The results suggest that VK2735 could offer a more convenient dosing schedule without sacrificing efficacy, potentially improving patient adherence. This could disrupt the current market leaders and expand the addressable market for GLP-1/GIP agonists, particularly if oral formulations prove effective in later trials.

What to watch

Viking plans to initiate an oral Phase 3 trial later in 2026 and will continue evaluating higher doses and less frequent dosing regimens. The company has a cash position of $502 million to fund these trials. Investors will watch for the results of the oral maintenance dosing study and any updates from the Phase 3 Vanquish program.